Deep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients
- PMID: 32911110
- PMCID: PMC7476444
- DOI: 10.1016/j.jvsv.2020.08.028
Deep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients
Abstract
Background: Venous thromboembolic events have been one of the main causes of mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia. The aim of our study was to describe the prevalence of deep vein thrombosis (DVT) in noncritically ill patients with COVID-19 pneumonia and correlate such observations with the thromboprophylaxis received.
Methods: We performed a prospective cohort study of 67 patients admitted to the hospital for COVID-19 pneumonia. The diagnosis was confirmed using polymerase chain reaction testing of nasopharyngeal specimens. The deep veins were examined using compression duplex ultrasonography with the transducer on B-mode. The patients were separated into two groups for statistical analysis: those receiving low-molecular-weight heparin prophylaxis and those receiving intermediate or complete anticoagulation treatment. Risk analysis and logistic regression were performed.
Results: Of the 67 patients, 57 were included in the present study after applying the inclusion and exclusion criteria; 49.1% were women, and the patient mean age was 71.3 years. All 57 patients had undergone compression duplex ultrasonography. Of these 57 patients, 6 were diagnosed with DVT, for an in-hospital rate of DVT in patients with COVID-19 pneumonia of 10.5%. All the patients who had presented with DVT had been receiving low-molecular-weight heparin prophylaxis. The patients receiving prophylactic anticoagulation treatment had a greater risk of DVT (16.21%; 95% confidence interval, 0.04-0.28; P = .056) compared with those receiving intermediate or complete anticoagulation treatment. We also found a protective factor for DVT in the intermediate or complete anticoagulation treatment group (odds ratio, 0.19; 95% confidence interval, 0.08-0.46; P < .05).
Conclusions: Noncritically ill, hospitalized patients with COVID-19 pneumonia have a high risk of DVT despite receipt of correct, standard thromboprophylaxis.
Keywords: COVID-19 pneumonia; Deep vein thrombosis; Thromboprophylaxis.
Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Deep vein thrombosis in hospitalized patients with coronavirus disease 2019.J Vasc Surg Venous Lymphat Disord. 2021 May;9(3):597-604. doi: 10.1016/j.jvsv.2020.09.010. Epub 2020 Oct 8. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33039545 Free PMC article.
-
DVT incidence and risk factors in critically ill patients with COVID-19.J Thromb Thrombolysis. 2021 Jan;51(1):33-39. doi: 10.1007/s11239-020-02181-w. J Thromb Thrombolysis. 2021. PMID: 32607652 Free PMC article.
-
Incidence of deep venous thrombosis in COVID-19 critically ill patients treated with intermediate-dose of heparin for thromboprophylaxis: The COVIDOP-DVT observational study.Vascular. 2024 Oct;32(5):1099-1106. doi: 10.1177/17085381231165083. Epub 2023 Apr 3. Vascular. 2024. PMID: 37009990 Free PMC article.
-
Deep vein thrombosis and its prevention in critically ill adults.Arch Intern Med. 2001 May 28;161(10):1268-79. doi: 10.1001/archinte.161.10.1268. Arch Intern Med. 2001. PMID: 11371254 Review.
-
Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials.Clin Exp Med. 2023 Aug;23(4):1189-1196. doi: 10.1007/s10238-022-00876-3. Epub 2022 Sep 1. Clin Exp Med. 2023. PMID: 36048371 Free PMC article.
Cited by
-
Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients.Ther Adv Neurol Disord. 2022 May 24;15:17562864221099472. doi: 10.1177/17562864221099472. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 35646159 Free PMC article.
-
COVID-19 and thrombosis: From bench to bedside.Trends Cardiovasc Med. 2021 Apr;31(3):143-160. doi: 10.1016/j.tcm.2020.12.004. Epub 2020 Dec 16. Trends Cardiovasc Med. 2021. PMID: 33338635 Free PMC article. Review.
-
Venous thromboembolism in COVID-19: A systematic review and meta-analysis.Vasc Med. 2021 Aug;26(4):415-425. doi: 10.1177/1358863X21995566. Epub 2021 Apr 4. Vasc Med. 2021. PMID: 33818197 Free PMC article.
-
Venous thromboembolism in viral diseases: A comprehensive literature review.Health Sci Rep. 2023 Feb 5;6(2):e1085. doi: 10.1002/hsr2.1085. eCollection 2023 Feb. Health Sci Rep. 2023. PMID: 36778773 Free PMC article.
-
The Impact of COVID-19 on Graft Vasculopathy and Postoperative Thromboembolism in CABG Patients: A Prospective Controlled Study.Cardiovasc Toxicol. 2025 Aug;25(8):1123-1138. doi: 10.1007/s12012-025-10017-3. Epub 2025 Jun 10. Cardiovasc Toxicol. 2025. PMID: 40495032 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical